NCIt definition : A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable
fragments (scFv), one directed against the tumor-associated antigen (TAA) human B-cell
maturation antigen (BCMA; TNFRSF17), fused to one that is directed against the CD3
antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic
activities. Upon administration of pavurutamab, this bispecific antibody binds to
both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor
cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results
in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the
tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant
plasma cells, plays a key role in promoting plasma cell survival.;
UNII : GLR3JG8TZU;
CAS number : 2250292-39-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2250292-39-6
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;